

Customer No. 28880

Confirmation No.

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/731/707	
	Filing Date	12/9/2003	
	First Named Inventor	Usa Datta, et al	
	Art Unit	TBD	
	Examiner Name	TBD	
Total Number of Pages in This Submission	6	Attorney Docket Number	PC 10940B

RECEIVED  
CENTRAL FAX CENTER  
MAR 03 2004

OFFICIAL

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to a Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): IDS Statement
Remarks AUTHORIZATION TO CHARGE THE FEE AND ANY ADDITIONAL FEES AS NECESSARY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT 23-0455 IS HEREBY GIVEN.		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	J. Michael Dixon
Signature	<i>J. Michael Dixon</i> # 32,410
Date	March 3, 2004

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date	
Typed or printed	Cicely M. Bohms
Signature	<i>Cicely M. Bohms</i>
Date	March 3, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPTO Fax No. 703-872-9306

RECEIVED  
CENTRAL FAX CENTER

MAR 03 2004

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/731,707  
Applicant: USA DATTA, ET AL  
Filed: December 9, 2003  
Title: 3-OX(AD)AZOLYLPROPANOHYDROXAMIC  
USEFUL AS PROCOLLAGEN C-PREOTEINASE INHIBITORS

ACIDS

TC/A.U.: TBD  
Examiner: TBD

Docket No.: PC10940B

Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d); within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114.

*In accordance with 37 C.F.R. §1.98(d), a copy of each document or other information listed is not provided because it was previously cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. filed on .*

A concise explanation of the relevance of each non-English language document or other information is as follows (37 C.F.R. §1.98(a)(3)):

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. §1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Authorization is hereby given to charge the required fee under 37 C.F.R. §1.17(p), any other necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,



Dated: March 3, 2004

J. Michael Dixon, Reg. No. 32,410  
Warner-Lambert Company  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Tel. (734) 622-1705  
Fax (734) 622-1553  
Customer No. 28880





FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PC10940A	SERIAL NO. 10/021,721
		APPLICANT USA DATTA, ETAL.	
		FILING DATE DECEMBER 12, 2001	GROUP 1614

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6 4 4 8 2 7 8	9/10/02	Bailey et al.	514	364	

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
9 5 2 3 7 9 0	08.09.95	WO			
0 1 4 7 9 0 1	05.07.01	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

	Dankwardt et al., "Solid-Phase Synthesis of Di- and Tripeptidic Hydroxamic Acids as Inhibitors of Procollagen C-proteinase", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 10, pages 2513-2516, 2000
	Fray and Ellis, "Application of Epimerisation-Free Amide Copuling Conditions to the Synthesis of Matrix Metalloproteinase Inhibitor Intermediates", <i>Tetrahedron</i> , Vol. 54, pages 13825-13832, 1998
	Fray et al., "Selectivity of Inhibition of Matrix Metalloproteinases MMP-3 and MMP-2 by Succinyl Hydroxamates and their Carboxylic Acid Analogues is Dependent on P3' Group Chirality", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 11, pages 567-570, 2001
	Yamamoto et al., "Inhibition of Membrane-Type 1 Matrix Metalloproteinase by Hydroxamate Inhibitors: An Examination of the Subsite Pocket", <i>J. Med. Chem.</i> , Vol. 41, No. 8, pages 1209-1217, 1998

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.